Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andreas Petry has a total of 165 co-authors. Here are the top co-authors by number of shared publications:

  • Agnes Görlach

    Experimentelle Kinderkardiologie, Deutsches Herzzentrum München an der Technischen Universität München, Munich, Germany

    3 shared publications
  • A. Suha Yalçın

    Department of Biochemistry, School of Medicine, Marmara University, Istanbul, Turkey

    1 shared publication
  • Afroditi Chatzi

    Institute of Molecular Cell and Systems Biology, College of Medical Veterinary and Life Sciences, University of Glasgow, University Avenue, Glasgow, UK

    1 shared publication
  • Agnes Görlach

    Experimentelle und Molekulare Kinderkardiologie, Deutsches Herzzentrum München, TU München, München, Deutschland

    1 shared publication
  • Alberto Bindoli

    Institute of Neuroscience (CNR), Padova, Italy

    1 shared publication
  • Aleksandra Pavićević

    Faculty of Physical Chemistry, University of Belgrade, Studentski trg 12-16, Belgrade, Serbia

    1 shared publication

Latest Publications

  • Open Access

    Role of Endogenous Myoglobin in Anthracycline Response in Breast Cancer

    by Ilona Rybinska, Andreas Petry, Thomas Hankeln, Thomas A. Gorr, Gaetano Cairo

    Anthracyclines such as doxorubicin (DOX) remain central components of breast cancer (BC) chemotherapy, although their efficacy is frequently limited by drug resistance. Myoglobin (MB), an oxygen-binding heme protein expressed in breast tumors, has been implicated in the detoxification of DOX in cardiomyocytes, but its role in BC remains unclear. Using MB-expressing and MB-knockout (MBKO) MDA-MB-468 BC cells, we demonstrate that MB confers hypoxia-dependent resistance to DOX. Under hypoxia, MB-expressing cells exhibited reduced intracellular DOX-associated fluorescence, enhanced superoxide generation, and decreased sensitivity to DOX, findings consistent with altered redox cycling and oxidative processing of the drug. Re-expression of MB in MBKO cells restored resistance, whereas pharmacological modulation of MB function using carbon monoxide-releasing molecule-3 and tert-butoxycarbonyl-alanine reversed MB-dependent reductions in intracellular DOX accumulation. In contrast, aclarubicin, an anthracycline lacking the hydroquinone moiety required for efficient redox cycling, failed to reproduce MB-dependent effects. Analyses of four independent neoadjuvant BC cohorts further demonstrated that elevated MB expression was consistently associated with reduced probability of achieving pathological complete response following anthracycline-containing chemotherapy. Collectively, these findings identify MB as a previously unrecognized modulator of BC response to redox-active anthracyclines and support its potential utility as both a predictive biomarker and therapeutic target.

  • Open Access

    Inflammation and Fibrosis in Progeria: Organ-Specific Responses in an HGPS Mouse Model

    by Peter Krüger, Moritz Schroll, Felix Fenzl, Eva-Maria Lederer, Ramona Hartinger, Rouven Arnold, Deniz Cagla Togan, Runjia Guo, Shiyu Liu, Andreas Petry, et al.

    Hutchinson–Gilford Progeria Syndrome (HGPS) is an extremely rare genetic disorder that causes accelerated aging, due to a pathogenic variant in the LMNA gene. This pathogenic results in the production of progerin, a defective protein that disrupts the nuclear lamina’s structure. In our study, we conducted a histopathological analysis of various organs in the LmnaG609G/G609G mouse model, which is commonly used to study HGPS. The objective of this study was to show that progerin accumulation drives systemic but organ-specific tissue damage and accelerated aging phenotypes. Our findings show significant fibrosis, inflammation, and dysfunction in multiple organ systems, including the skin, cardiovascular system, muscles, lungs, liver, kidneys, spleen, thymus, and heart. Specifically, we observed severe vascular fibrosis, reduced muscle regeneration, lung tissue remodeling, depletion of fat in the liver, and disruptions in immune structures. These results underscore the systemic nature of the disease and suggest that chronic inflammation and fibrosis play crucial roles in the accelerated aging seen in HGPS. Additionally, our study highlights that each organ responds differently to the toxic effects of progerin, indicating that there are distinct mechanisms of tissue-specific damage.


  • Open Access

    NADPH-Oxidasen und HIF: zentrale Elemente der Redoxhomöostase

    by Andreas Petry, Agnes Görlach

    Reactive oxygen species (ROS) are not only toxic agents but also potent signaling molecules. NADPH oxidases are the sole enzymes to generate ROS playing an important role in redox signaling. They closely interact in several ways with hypoxia-inducible transcription factors of the HIF family. This signaling network is active under normoxic and hypoxic conditions as an important regulator of redox homeostasis. Members of the NADPH oxidases-HIF axis appear as interesting therapeutic targets for various disorders characterized by an impaired redox homeostasis.


  • Regulation of NADPH Oxidases by G Protein-Coupled Receptors

    by Andreas Petry, Agnes Görlach

    Significance: G protein-coupled receptors (GPCR) are the largest group of cell surface receptors, which link cells to their environment. Reactive oxygen species (ROS) can act as important cellular signaling molecules. The family of NADPH oxidases generates ROS in response to activated cell surface receptors. Recent Advances: Various signaling pathways linking GPCRs and activation of NADPH oxidases have been characterized. Critical Issues: Still, a more detailed analysis of G proteins involved in the GPCR-mediated activation of NADPH oxidases is needed. In addition, a more precise discrimination of NADPH oxidase activation due to either upregulation of subunit expression or post-translational subunit modifications is needed. Also, the role of noncanonical modulators of NADPH oxidase activation in the response to GPCRs awaits further analyses. Future Directions: As GPCRs are one of the most popular classes of investigational drug targets, further detailing of G protein-coupled mechanisms in the activation mechanism of NADPH oxidases as well as better understanding of the link between newly identified NADPH oxidase interaction partners and GPCR signaling will provide new opportunities for improved efficiency and decreased off target effects of therapies targeting GPCRs.


  • Open Access

    European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)

    by Javier Egea, Isabel Fabregat, Yves M. Frapart, Pietro Ghezzi, Agnes Görlach, Thomas Kietzmann, Kateryna Kubaichuk, Ulla G. Knaus, Manuela G. Lopez, Gloria Olaso-Gonzalez, et al.